This stock is vertualy unknown to investors.
EU approval next year will be huge
Medasorb ( MSBT.OB )
MarketCap : 2,4 Mio US$
Cash : 2,9 Mio US$
Price : 0,07 $
Shares Out : 30,5 million ( 59% held by Insider )
CytoSorbents, Inc. Recognized as "Company Most Likely to Succeed" at the 2009 New Jersey Venture Conference and Provides Clinical Update
MONMOUTH JUNCTION, NJ--(MARKET WIRE)--Mar 30, 2009 -- CytoSorbents, Inc., the wholly-owned operating subsidiary of MedaSorb Technologies Corporation (OTC BB:MSBT.OB - News), announced it was chosen as "Company Most Likely to Succeed" by independent judges at the 2009 New Jersey Technology Council Venture Conference on March 27, 2009. The Company was one of 60 healthcare and technology companies presenting at the conference who were eligible for this coveted all-around award. "We feel extremely honored to have received this award, particularly against such solid competition," stated Dr. Phillip Chan, CEO. "It is especially gratifying that others recognize the significant value we are building and the potential of our technology to treat severe sepsis, one of the top medical causes of death in the world. We are committed to increasing shareholder value by making significant progress on key milestones and objectives, including our European Sepsis Trial. Among other means, we will continue to foster increased awareness of our Company through venues such as the New Jersey Technology Council Venture Conference and the In3 West Conference that we presented at in early March. Our story has been getting stronger and has been well-received because it is based on compelling science and our unique CytoSorb(TM) blood purification technology."
CytoSorbents provides the following clinical update on its current European Sepsis Trial:
-- Twenty-two patients have been enrolled to date from three trial sites.
-- Recruitment is now expected to accelerate with a current total of ten
initiated clinical sites.
-- The CytoSorb(TM) treatment has been well-tolerated by patients and
easily administered by hospital staff on standard dialysis equipment.
-- There have been no serious device related adverse events associated
with CytoSorb(TM) treatment in more than 450 human treatments,
approximately 90 of which have been in septic patients.
-- The Company continues to expect trial completion in 2009 with the goal
of CE Mark approval and initial commercial sales in Europe next year.
-----------------
RedChip Visibility Initiates Research On MedaSorb Technologies
2006-08-22 13:49 ET - News Release
ORLANDO, Fla., Aug. 22, 2006 (PRIMEZONE) -- RedChip Visibility, a division of RedChip Companies, announced today that they have initiated research on MedaSorb Technologies (OTCBB:MSBT).
Patrick Murphy, CFA, RedChip Research Analyst, wrote in the report:
"We believe it is reasonable to expect that MedaSorb will get its products to market in the time frame projected by management, and that the upside potential is more than sufficient to justify the many risks associated with an investment today. Assuming CytoSorbT (MedaSorb's primary product which is used in the treatment of the symptoms associated with sepsis, cardiopulmonary bypass surgery, organ donation transplantation, and drug overdoses.) makes it to market in 3 years, MedaSorb will be worth at least $375 million, 3 years from now."
$0.0 (05/29/09)
